Links to Data sources

Sr. No Display Name Type Country Last Updated
1 CPRD Data Source United Kingdom 05/06/2019

Links to Studies

Status Official Title Lead Investigator Last Updated
Finalised WWE117397: Post-authorization safety Electronic Medical Records database retrospective cohort study of new users of inhaled UMEC/VI or new users of inhaled UMEC in the primary care setting: UK EMR distributed network study Mr Daniel Dedman 17/05/2021
Finalised Aclidinium Bromide Drug Utilisation Post-Authorisation Safety Studies (DUS): Common Protocol for Aclidinium (DUS1) and Aclidinium/Formoterol Fixed-Dose Combination (DUS2) Dr Cristina Rebordosa 26/01/2021
Finalised Ability of primary care health databases to assess medicinal products discussed by the European Union Pharmacovigilance Risk Assessment Committee Mr Robert Flynn 20/02/2020
Finalised Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus, Pimecrolimus, and Corticosteroids Dr Alejandro Arana 22/11/2019
Finalised Drug utilization study of mirabegron (Betmiga®) using real-world healthcare databases from the Netherlands, Spain, United Kingdom and Finland Dr Ron Herings 02/05/2019
Finalised A drug utilisation study of Rifaxamin-╬▒ 550mg Ms Jennifer Campbell 28/02/2019
Finalised Evaluation of potential off-label use of dabigatran etexilate in Europe Dr Manel Pladevall-Vila 20/09/2018
Finalised Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus, Pimecrolimus, and Corticosteroids Dr Jordi Castellsague 15/05/2018
Finalised Pan European Multi-Database Bladder Cancer Risk Characterisation Study Dr Pasi Korhonen 30/05/2017
Ongoing Post-authorisation safety study in patients with type 2 diabetes mellitus to assess the risk of acute liver injury, acute kidney injury and chronic kidney disease, severe complications of urinary tract infection, genital infections, and diabetic ketoacidosis among patients treated with empagliflozin compared to patients treated with DPP-4 inhibitors Dr Cristina Rebordosa 05/11/2021
Ongoing Methods for controlling by indication for prescriptions: application to medications for neuropathic pain Dr Christine Damase-Michel 04/10/2021
Ongoing VALIDATION STUDY PROTOCOL (OP0007) FOR THE EUROPEAN NON-INTERVENTIONAL POST- AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS CARDIOVASCULAR EVENTS OF MYOCARDIAL INFARCTION AND STROKE AND ALL-CAUSE MORTALITY FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE (OP0004) AND EUROPEAN NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS INFECTIONS FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE (OP0006) Dr Clinical Trial Registries and Results Personal data of lead investigator will not be disclosed because his/her consent required for disclosure according to applicable data protection laws is not available. 29/10/2020
Ongoing EUROPEAN NON-INTERVENTIONAL POST AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS INFECTIONS FOR ROMOSOZUMAB BY THE EU ADR ALLIANCE Dr Clinical Trial Registries and Results Personal data of lead investigator will not be disclosed because his/her consent required for disclosure according to applicable data protection laws is not available. 29/10/2020
Ongoing EUROPEAN NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY RELATED TO ADHERENCE TO THE RISK MINIMIZATION MEASURES FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE Dr Clinical Trial Registries and Results Personal data of lead investigator will not be disclosed because his/her consent required for disclosure according to applicable data protection laws is not available. 29/10/2020
Ongoing European non-interventional post-authorization safety study related to serious cardiovascular events of myocardial infarction and stroke, and all-cause mortality for romosozumab by the EU-ADR Alliance Dr Clinical Trial Registries and Results Personal data of lead investigator will not be disclosed because his/her consent required for disclosure according to applicable data protection laws is not available. 29/10/2020
Ongoing Incidence of Thyroid Neoplasm and Pancreatic Cancer in Type 2 Diabetes Mellitus Patients who Initiate Once Weekly Exenatide Compared with Other Antihyperglycemic Drugs Ms Tarita Murray-Thomas 19/05/2017
Planned Demonstrating solutions for studying intermittent medication exposures in diseases with episodic manifestations during pregnancy: application to medication for migraine in pregnancy Professor Hedvig Nordeng 04/10/2021
Planned An observational cohort study to describe intermittent OCS utilisation and its association with adverse outcomes and healthcare resource use and costs in asthma using the OPCRD and CPRD databases. Professor David Price 04/09/2020